The specific thresholds that should prompt dose reduction or discontinuation include: ALT or AST elevation exceeding 3 times the patient's baseline value, new or worsening coagulopathy (INR increase of 0.5 or more from baseline), albumin decline below 2.5 g/dL, or new clinical signs of hepatic decompensation such as worsening ascites, encephalopathy, or jaundice [5]
All these ingredients have been extensively studied for their ability to heal leaky gut
And, Ive summarized the cost/benefit trade-off, detailing for whom the benefits may far outweigh the risks, at least in the short term
The peptide cycling research overview covers the desensitization considerations relevant to extended dosing for this combinations protocols
If a provider determines you aren't a good candidate, they should explain the reason and discuss alternatives
10.5344/ajev.1965.16.3.144 135 SingletonV